Full-Time

Medical Science Liaison

Dermatology, Long Island

Posted on 9/11/2026

Deadline 9/18/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$117k - $201.3k/yr

+ Long-term incentive program

Central Islip, NY, USA

In Person

Supports a specific territory with up to 70% travel, including internal meetings and congresses.

PharmD, PhD, MD

Category
Biology & Biotech

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A doctorate-level degree or equivalent experience is required, including PharmD, PhD, MD, or advanced practice provider qualifications.
  • Postgraduate experience is required for doctoral-level candidates, with preference for therapeutic-area clinical experience.
  • Demonstrated in-depth scientific and/or therapeutic knowledge.
  • Knowledge of research and/or health care systems.
  • Proficiency in data gathering and analysis, clinical expertise, problem solving, interpersonal influence, cross-functional collaboration, strategic thinking, and competitive landscape analysis.
  • Ability to support a specific territory with up to 70% travel, including travel within the territory and for internal meetings and congresses.
  • Must hold a valid United States driver's license.
Responsibilities
  • Develop and implement a scientific engagement plan for the territory that aligns with Medical Affairs strategy, prioritized medical objectives, and approved core medical assets.
  • Cultivate professional relationships with community and academic opinion leaders and key opinion leaders in the territory.
  • Engage in high-quality, two-way scientific exchange in the relevant disease area.
  • Use MSL tools to develop a strategic approach to customer engagements by collecting, synthesizing, and applying clinical, scientific, competitive, and territory-level information.
  • Leverage artificial intelligence tools and insights to enhance decision-making, streamline processes, and improve efficiency and outcomes.
  • Maintain awareness of direct and indirect competitors within the therapeutic area and incorporate relevant, evidence-based clinical context into scientific engagement planning and compliant scientific discussions.
  • Deliver relevant scientific data tailored to health care professional needs through dialogue and presentations that translate complex clinical evidence into meaningful scientific discussion.
  • Engage health care providers and internal partners to identify challenges or unmet needs and collaboratively propose evidence-based solutions or educational initiatives.
  • Identify, collect, and submit high-quality actionable insights in a timely manner to inform medical strategy and cross-functional territory-level discussions.
  • Respond to unsolicited inquiries about Johnson & Johnson products and research from external stakeholders.
  • Provide point-of-contact support to investigators and internal partners for company-sponsored and investigator-initiated studies.
  • Collaborate compliantly with internal stakeholders in a matrixed environment to support Medical Affairs objectives and scientific exchange activities, including coordination with MSL field partners, Research and Development, United States and Global Medical Affairs, Clinical Operations, and appropriately defined interactions with Sales and Marketing.
  • Maintain scientific acumen through self-reading, journal clubs, educational seminars, local and national congresses, and scientific discussions with peers.
  • Foster inclusion and belonging internally and externally to support engagement, productivity, and innovation.
  • Develop competence in regulatory and health care compliance guidelines, corporate policies on business conduct and ethical behavior, and Medical Affairs standard operating procedures and guidelines.
  • Collaborate with the Field Director to develop and implement a performance and development plan and contribute to additional leadership or enterprise initiatives.
  • Complete administrative requirements accurately and compliantly, including activity documentation and expense reporting.
Desired Qualifications
  • Relevant experience of at least two years, preferably in a Medical Science Liaison role.
  • At least two years of therapeutic-area experience.
  • Residency or fellowship experience.
  • Board certification for clinical degrees.
  • Demonstrated commitment to learning emerging technologies such as artificial intelligence through exploration, iteration, and applying new tools over time.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.